Notably, antibody blocking of the pro-inflammatory cytokine IL-1β reduced the risk of major adverse cardiovascular events among those with CKD (9, 10), demonstrating the potential of reducing chronic inflammation to reduce CV risk. Here, IL1B is linked to chronic kidney disease.